Authors
Latest:
Embracing Programmatic Advertising to Enhance Targeting of HCPsThe precision of programmatic advertising is reshaping the way life sciences brands engage with healthcare professionals, offering enhanced personalization, scale, and optimization in today's digital landscape.
Latest:
Beyond the Data: Is Blockchain the Answer to Improving Global Health?The COVID-19 pandemic has shifted the adoption of digital platforms in pharma and has made the industry reconsider which technologies can improve global health moving forward.
Latest:
Using ML, AI and RWD to Infer HCP SpecialtiesPharmaceutical sales operations teams often rely on outdated or inaccurate data when prioritizing HCP targets, limiting promotional effectiveness. By applying artificial intelligence and machine learning to real world data, pharmaceutical companies can more effectively target physicians hiding in plain sight and PCPs behaving like specialists.
Latest:
The Potential of ProteomicsMajor stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.
Latest:
The Polymath: A New Commercial Role in the Pharma IndustryPharma requires leaders who are "polymaths" — that is, those with the breadth and depth of experience within each of the sub-functions of commercial operations. Niti Sawhney reports.
Latest:
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent ContractorsPharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Latest:
Exploring the Advantages of Innovative Early Phase Trial DesignIn early phase trials innovative designs offer potential for improvements in efficiency and decision-making.
Latest:
CMS Signals Looming Sunshine Act Audits: How to PrepareNew guidance suggests that CMS may be ramping up Sunshine Act auditing activities, potentially resulting in monetary liability for noncompliant reporting entities.
Latest:
Manage Risk Effectively to Improve the Value of Your AllianceIn this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Latest:
The Diversity Mindset: Benefits of Tapping External SourcesSeeking opportunities to be more inclusive can help pharma companies gain a deeper understanding of key opinion leader and patient perspectives and build diversity into the entire product journey.
Latest:
Maintaining Supply Chain Resiliency, No Matter the CircumstancesThe formula for future-proofing pharmaceutical networks to withstand any disruption.
Latest:
The 8 Market Access Performance Metrics You Should Be TrackingThis guide offers an in-depth analysis of the essential KPIs that market access teams should track to measure success particularly across speed of access, breadth of access, and price performance. It includes real-life use cases and practical steps on how to get started.
Latest:
Why Medical Engagement With Key Opinion Leaders Drives Treatment Adoption: Q&A with Dan Rizzo, global head of Veeva business consultingWith treatments becoming more complex, the life sciences industry needs more professionals with specialized knowledge.
Latest:
IDNs — So What?The U.S. healthcare system has undergone significant changes, particularly in the pharmaceutical industry, due to factors like telemedicine, integrated delivery networks, and value-based care. This has challenged traditional sales models and increased the need for more strategic engagement with clinical executives.
Latest:
Scale Down Before Scaling Up: Digital Innovation in a Highly Regulated IndustryThe highly-regulated pharmaceutical industry poses serious challenges that can derail digital health programs. But, there are solutions.
Latest:
Combining Regulatory Pathways to Optimize Development EfficiencyMultiple regulatory pathways exist during the drug development process.
Latest:
MSL Teams Need to Digitize, or Face Being Left BehindMedical science liaisons (MSL) in the pharma industry were already at their limit pre-COVID. The challenge for MSLs is to identify the most efficient way to upskill their teams and add digital competencies without overloading them.
Latest:
Sustainability and Progress Continue to Make Headlines in 2024Recognition of the business case for ESG in pharma is soaring.
Latest:
Measuring Omnichannel Efforts in Medical AffairsA five-step pilot approach to effective measurement of medical affairs omnichannel efforts.
Latest:
Final ThoughtsThe future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Latest:
The State of Mining Data Insights in the Life Sciences Industry – 2024 (April 2024)A recent industry-wide survey reveals disconnects and unmet needs pertaining to real-world patient data and analytics that can impact business decision making.
Latest:
Current Status of Biosimilars and Their Impact on PharmacovigilanceAs the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.
Latest:
Translating ‘Digital-First’ to Commercial SuccessWhy a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.
Latest:
Sustaining Pace With Contingent WorkersPandemic workforce trends continue to create challenges for pharma.
